Tissue expression of transforming growth factor-β1 and its receptors: correlation with pathologic features and biochemical progression in patients undergoing radical prostatectomy - 23/08/11
Abstract |
Objectives |
To determine whether the abnormal expression of transforming growth factor-beta1 (TGF-β1) and/or its receptors (TGFβ-RI and TGFβ-RII) is associated with prostate cancer features and progression; and to investigate the relationship between tissue expression of TGFs and blood levels of TGF-β1.
Methods |
Immunohistochemical staining for TGF-β1, TGFβ-RI, and TGFβ-RII was carried out on archival specimens from 118 consecutive patients who underwent radical prostatectomy for clinically localized disease (median follow-up 57.5 months). Preoperative plasma TGF-β1 levels were also measured.
Results |
TGF-β1 was overexpressed in 71 (60%) of 118 patients, and TGFβ-RI and TGFβ-RII expression was decreased in 34 (29%) and 39 (33%) of 118 patients, respectively. Of the 118 patients, 82 (70%) had abnormal expression of at least one of the three TGFs and 22 (19%) had abnormal expression of all three. The concordance rates between the expression of TGF-β1 and its receptors were 54% and 62%. Abnormal expression of all three TGFs was significantly associated with extracapsular disease. However, only decreased expression of TGFβ-RI and TGFβ-RII was significantly associated with seminal vesicle involvement and greater pathologic Gleason score. Preoperative plasma TGF-β1 levels were significantly elevated in patients with abnormal expression of TGFs. TGFβ-RI expression and surgical margin status were independently associated with biochemical progression.
Conclusions |
Our results showed that abnormal expression of TGF-β1 and its receptors is common in prostate cancer. TGF-β1 overexpression is moderately but significantly associated with a loss of expression of TGFβ-RI and TGFβ-RII. Loss of TGFβ-RI expression is a prognostic marker in patients with prostate cancer.
Le texte complet de cet article est disponible en PDF.Plan
 | Shahrokh F. Shariat is supported by the Austrian Program for Advanced Research and Technology. |
Vol 63 - N° 6
P. 1191-1197 - juin 2004 Retour au numéro
Article précédent
- Expression of insulin-like growth factor binding protein-3 before and after neoadjuvant hormonal therapy in human prostate cancer tissues: correlation with histopathologic effects and biochemical recurrence
- Yasuyoshi Miyata, Hideki Sakai, Shigeru Kanda, Tsukasa Igawa, Tomayoshi Hayashi, Hiroshi Kanetake
- c-FLIP expression in bladder urothelial carcinomas: its role in resistance to Fas-mediated apoptosis and clinicopathologic correlations
- Penelope Korkolopoulou, Athina Goudopoulou, Gerassimos Voutsinas, Euphemia Thomas-Tsagli, Panagiotis Kapralos, Efstratios Patsouris, Angelica A. Saetta
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?